CN103505457B - Application of stachys sieboldii extract - Google Patents
Application of stachys sieboldii extract Download PDFInfo
- Publication number
- CN103505457B CN103505457B CN201310261724.7A CN201310261724A CN103505457B CN 103505457 B CN103505457 B CN 103505457B CN 201310261724 A CN201310261724 A CN 201310261724A CN 103505457 B CN103505457 B CN 103505457B
- Authority
- CN
- China
- Prior art keywords
- extract
- mountain
- soviet union
- prostate
- mountain soviet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000284 extract Substances 0.000 title claims abstract description 100
- 241000424764 Stachys affinis Species 0.000 title abstract 4
- 235000005116 Stachys sieboldii Nutrition 0.000 title abstract 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 29
- 239000003814 drug Substances 0.000 claims abstract description 24
- 238000000605 extraction Methods 0.000 claims abstract description 16
- 239000000203 mixture Substances 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 13
- 238000004440 column chromatography Methods 0.000 claims abstract description 11
- 238000000638 solvent extraction Methods 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- -1 pyropheophorbide-alpha methyl ester Chemical class 0.000 claims abstract description 6
- 238000004108 freeze drying Methods 0.000 claims abstract description 5
- 210000002307 prostate Anatomy 0.000 claims description 43
- 206010020718 hyperplasia Diseases 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 9
- 201000001514 prostate carcinoma Diseases 0.000 claims description 9
- 230000037396 body weight Effects 0.000 claims description 8
- UELITFHSCLAHKR-UHFFFAOYSA-N acibenzolar-S-methyl Chemical compound CSC(=O)C1=CC=CC2=C1SN=N2 UELITFHSCLAHKR-UHFFFAOYSA-N 0.000 claims description 6
- 239000012467 final product Substances 0.000 claims description 6
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 5
- 235000020778 linoleic acid Nutrition 0.000 claims description 5
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 5
- 229960004488 linolenic acid Drugs 0.000 claims description 5
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 5
- 239000013543 active substance Substances 0.000 claims description 4
- 238000004587 chromatography analysis Methods 0.000 claims description 4
- 238000005266 casting Methods 0.000 claims description 3
- 238000001742 protein purification Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 abstract description 10
- 238000011282 treatment Methods 0.000 abstract description 5
- 239000002904 solvent Substances 0.000 abstract description 3
- 208000017497 prostate disease Diseases 0.000 abstract description 2
- 244000124853 Perilla frutescens Species 0.000 abstract 1
- 235000004348 Perilla frutescens Nutrition 0.000 abstract 1
- 238000013375 chromatographic separation Methods 0.000 abstract 1
- 150000004702 methyl esters Chemical class 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 18
- 206010060862 Prostate cancer Diseases 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 239000003098 androgen Substances 0.000 description 10
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 208000025844 Prostatic disease Diseases 0.000 description 8
- 238000010586 diagram Methods 0.000 description 8
- 210000000651 myofibroblast Anatomy 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000001976 improved effect Effects 0.000 description 6
- 210000003708 urethra Anatomy 0.000 description 6
- 240000004435 Asplenium nidus Species 0.000 description 5
- 235000014256 Asplenium nidus Nutrition 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 240000006661 Serenoa repens Species 0.000 description 4
- 235000005318 Serenoa repens Nutrition 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000003651 drinking water Substances 0.000 description 4
- 235000020188 drinking water Nutrition 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 108091008039 hormone receptors Proteins 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000027939 micturition Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 201000007094 prostatitis Diseases 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 241000050051 Chelone glabra Species 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 206010020880 Hypertrophy Diseases 0.000 description 3
- 206010036018 Pollakiuria Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 2
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000737257 Pteris <genus> Species 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 2
- 229960004999 lycopene Drugs 0.000 description 2
- 235000012661 lycopene Nutrition 0.000 description 2
- 239000001751 lycopene Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 206010029446 nocturia Diseases 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 238000000194 supercritical-fluid extraction Methods 0.000 description 2
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- GFAZGHREJPXDMH-UHFFFAOYSA-N 1,3-dipalmitoylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCC GFAZGHREJPXDMH-UHFFFAOYSA-N 0.000 description 1
- FDKRLXBXYZKWRZ-UWJYYQICSA-N 3-[(21S,22S)-16-ethenyl-11-ethyl-4-hydroxy-12,17,21,26-tetramethyl-7,23,24,25-tetrazahexacyclo[18.2.1.15,8.110,13.115,18.02,6]hexacosa-1,4,6,8(26),9,11,13(25),14,16,18(24),19-undecaen-22-yl]propanoic acid Chemical compound CCC1=C(C2=NC1=CC3=C(C4=C(CC(=C5[C@H]([C@@H](C(=CC6=NC(=C2)C(=C6C)C=C)N5)C)CCC(=O)O)C4=N3)O)C)C FDKRLXBXYZKWRZ-UWJYYQICSA-N 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 241001453169 Asplenium Species 0.000 description 1
- 241000134125 Asplenium antiquum Species 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- VBCPVIWPDJVHAN-UHFFFAOYSA-N Phenoxybenzamine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C[NH+](CCCl)C(C)COC1=CC=CC=C1 VBCPVIWPDJVHAN-UHFFFAOYSA-N 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 235000000719 Prunus africana Nutrition 0.000 description 1
- 241000200478 Prunus africana Species 0.000 description 1
- 235000011158 Prunus mume Nutrition 0.000 description 1
- 244000018795 Prunus mume Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 108010081750 Reticulin Proteins 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- WNMJYKCGWZFFKR-UHFFFAOYSA-N alfuzosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CCCNC(=O)C1CCCO1 WNMJYKCGWZFFKR-UHFFFAOYSA-N 0.000 description 1
- 229960004607 alfuzosin Drugs 0.000 description 1
- 239000002160 alpha blocker Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000010293 colony formation assay Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- VJECBOKJABCYMF-UHFFFAOYSA-N doxazosin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 VJECBOKJABCYMF-UHFFFAOYSA-N 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000003652 hormone inhibitor Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- KWOKGUTUPNUAGP-AVRDEDQJSA-N methyl 3-[(21S,22S)-16-ethenyl-11-ethyl-4-hydroxy-12,17,21,26-tetramethyl-7,23,24,25-tetrazahexacyclo[18.2.1.15,8.110,13.115,18.02,6]hexacosa-1,4,6,8(26),9,11,13(25),14,16,18(24),19-undecaen-22-yl]propanoate Chemical compound CCC1=C(C2=NC1=CC3=C(C4=C(CC(=C5[C@H]([C@@H](C(=CC6=NC(=C2)C(=C6C)C=C)N5)C)CCC(=O)OC)C4=N3)O)C)C KWOKGUTUPNUAGP-AVRDEDQJSA-N 0.000 description 1
- 229940064639 minipress Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960003418 phenoxybenzamine Drugs 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- WFXFYZULCQKPIP-UHFFFAOYSA-N prazosin hydrochloride Chemical compound [H+].[Cl-].N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 WFXFYZULCQKPIP-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000037209 prostate health Effects 0.000 description 1
- 208000026455 prostate symptom Diseases 0.000 description 1
- 239000003087 receptor blocking agent Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000010018 saw palmetto extract Substances 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Abstract
A herba Stachydis Japonicae extract for preparing medicine or health food for improving prostate diseases comprises pyropheophorbide-alpha methyl ester, pheophorbide-alpha methyl ester, 1-linoleic acid-3-linolenic acid-glyceride, 1-linolenic acid-2, 3-dipalmitic acid-glyceride, and 1, 3-dipalmitic acid-glyceride. The perilla frutescens extract is prepared by a method comprising the following steps: a solvent extraction step of subjecting a Stachys sieboldii sample to extraction treatment using an extraction solvent so that the weight-to-volume ratio (w/v, g/ml) of the Stachys sieboldii sample to the extraction solvent is 50 to 60mg/ml, and recovering an extract; and a column chromatography step, namely performing chromatographic separation treatment on the extract by using water and ethanol as mobile phases to obtain a plurality of distinguishes, sequentially numbering sections a to i, selecting the sections b, c and d or a composition thereof, and performing reduced pressure concentration and freeze drying to obtain the stachys sieboldii extract.
Description
Technical field
The present invention is improving prostate disease with regard to a kind of purposes of plant extract especially with regard to a kind of mountain Soviet Union extract
The purposes of disease.
Background technology
Prostate at bladder outlet, surrounds urethra also known as prostate (Prostate), is the distinctive reproduction of male
One of organ.
Benign prostatauxe (Benign Prostatic Hyperplasia, abbreviation BPH) is common benign of male
Tumor, is apt to occur in the male of more than 50 years old, and its pathogenic machine turns not attaining clear yet, speculates increase with the age and hormone point at present
Secrete correlation.In general, the direct urethra of the enlarged meeting of prostate, cause urethra excess shrinkage, intrinsic pressure rising and cause row
Urine obstacle, such as urinary tract interruption, pollakiuria, leakage of urine and residual urine sense symptom, can cause uremia or renal failure when serious.Benign prostatitis
Though gland hypertrophy will not improve the risk of oj C prostate cancer, the symptom phase of right benign prostatauxe and carcinoma of prostate early stage
Closely, it is not easily distinguishable, probably misleads the correct diagnosis of carcinoma of prostate, delay is gone to a doctor or impact patient heart.
The treatment of existing benign prostatauxe can be dependent on excision or medicine, and pre- later stage of excision is longer and wind
Danger is slightly higher, therefore internal medicine medication is still main treatment meanss, common existing pharmaceutical pack sympathetic blocking agent containing A type
(alpha adrenergic blockers), such as Minipress, Dibenyline, Hytrin, Doxaben, Xatral, with
And hormone inhibitor, but, aforementioned two kinds of medicines all have the possibility of derivative side effect, may cause postural hypotension, urine
The problems such as incontinence, nasal obstruction, tired and sexual dysfunction, if also, the common drug is with other medicines and takes (such as coldrex, the heart
Angiopathy medication or hypotensor) more likely cause serious medical injury, cause patient's decocting unbearably.Additionally, separately having
Research points out that the long-term taking common drug can improve the probability for suffering from cancer (serious carcinoma of prostate and breast carcinoma), for patient more
It is to make the matter worse.
In recent years, the concept of nature recurrence and health care is risen from American-European countries so that traditional medicine
(traditional medicine, TM) or auxiliary alternative medicine (complementary and alternative
Medicine, CAM) it is gradually in fashion, therefore, the exploitation of Chinese traditional herbs Yu the natural plants related to prostatosis enjoys weight
Depending on having medical lycopene, Semen Cucurbitae, Serenoa repens (Saw Palmetto), African Fructus Ribis Alpestriss (Pygeum Africana) and Huang successively
The natural plants such as voxel or its composition have the report of obvious curative effects for male prostate health care, however, aforementioned natural plants
More it is effective in cure not substantially (as lycopene, Semen Cucurbitae it is limited for the therapeutic effect of prostatosis), or be limited to raw material product
The problems such as ground or extraction efficiency, such as Serenoa repens and African Fructus Ribis Alpestriss, only originate in Africa or the Atlantic Ocean, Caribbean bank, and raw material is obtained
It is difficult and extraction efficiency has variation with the position of extraction feed more again, thus undermines its application；Also, part natural plants
Probably there is the probability of derivative side effect, such as Serenoa repens easily cause stomach discomfort, nausea, constipation or diarrhoea and (extract automatic network data：
http://liaozhai.pujia.com/thread-500003-1.html), though unlikely cause serious sequela, eventually meeting
User is set not feel well, difficulty obtains conforming approval.
Therefore, if the medicinal plants that there is prostate hyperplasia significant curative effect can further be found, it is applied to treat and pre-
The exploitation of anti-medication, necessarily leads expectation by all circles, to be effectively improved human benign prostatic problem.
Mountain Soviet Union (Asplenium nidus L.) category Asplenium trchomanes L. class, is perennial large edible plant, originates in China
Taiwan and the band of Southeast Asia one, are often born in dark and damp trunk or rock is carefully sewed on, and at present in Taiwan various places, all on level land, agriculture has changed greatly
Amount volume production plantation.Traditional medicine is recorded, and mountain Soviet Union is adapted to rich in various nutritions and dietary fiber, mountain Soviet Union's tender leaf for subspecies food materials
In cooking, it is eaten for a long time safe, is modern's Constipation the effects such as with prophylaxis of hypertension, diabetes, colorectal cancer
Healthy vegetable, but has no it in the related report and application for improving prostatosis.
The content of the invention
The main object of the present invention is to provide a kind of mountain Soviet Union extract, containing the active skull cap components for suppressing androgen, can
It is effectively improved the related disease of male prostate.
A time purpose of the present invention is to provide a kind of mountain Soviet Union extract, for hormone receptor regulation and control have significantly regulation and control work(
Can, mountain Soviet Union extract is easy to obtain, is separated and can be applicable to improve the medicine group composition of male prostate or health food
Exploitation.
Another object of the present invention is to provide mountain Soviet Union extract is improving the purposes of prostatic diseases, and being will be aforesaid
Extract is revived as an active component in mountain, is applied to treat or prevent the medicine group composition or health food of prostatic diseases
Exploitation.
To reach aforementioned invention purpose, technological means that the present invention is used and by the technological means work(to be reached
Effect includes：
A kind of mountain Soviet Union extract, comprising Methyl Pyropheophorbide, Enfoliative cytologic, 1- linoleic acid -3-
Linolenic acid-glyceride, 1- linolenic acid -2,3- bis- Zong Beam-at-the-eaves acid-glyceride, and 1,3- bis- Zong Beam-at-the-eaves acid-glyceride.
The mountain Soviet Union extract of the present invention, wherein, extract is revived by obtained by a method for comprising the steps of in the mountain：One
Solvent extraction, is to use an extractant, and to a mountain Soviet Union sample extraction processing is carried out, and makes the mountain Soviet Union sample molten with the extraction
The w/v (w/v, g/ml) of agent is 50 to 60mg/mL, and reclaims to obtain an extract；And a col-umn chromatography step, profit
With water and ethanol as mobile phase, the chromatography for carrying out the extract is processed, and to obtain several differentiators, washing is successively compiled
Number it is section a to section i, picks and select section c Jing after concentrating under reduced pressure and lyophilization, obtains final product mountain Soviet Union extract.
The mountain Soviet Union extract of the present invention, wherein, the col-umn chromatography step selects section b Jing concentrating under reduced pressure and freezing dry to pick
After dry, the mountain Soviet Union extract is obtained final product.
The mountain Soviet Union extract of the present invention, wherein, the col-umn chromatography step selects section d Jing concentrating under reduced pressure and freezing dry to pick
After dry, the mountain Soviet Union extract is obtained final product.
The mountain Soviet Union extract of the present invention, wherein, the extractant of the solvent extraction is 95% ethanol.
The mountain Soviet Union extract of the present invention, wherein, the extractant of the solvent extraction is water.
The mountain Soviet Union extract of the present invention, wherein, the method further includes a selecting and purchasing step, i.e. choosing is plucked whole strain mountain Soviet Union flower and is containing root
The mountain Soviet Union sample.
And, a kind of purposes of mountain Soviet Union extract is that the mountain is revived extract as an active substance, is applied to prepare and uses
To treat the pharmaceutical compositions of prostatosis.
The purposes of the mountain Soviet Union extract of the present invention, is that the mountain is revived extract as an active substance, is applied to prepare and uses
To treat the health food of prostatosis.
The purposes of the mountain Soviet Union extract of the present invention, the prostatosis include prostate hyperplasia, carcinoma of prostate and prostate
It is scorching.
The purposes of the mountain Soviet Union extract of the present invention, wherein, mountain Soviet Union extract is to cast a bion with oral way.
The purposes of the mountain Soviet Union extract of the present invention, wherein, the amount of casting of mountain Soviet Union extract is daily per unit body weight
(kg) the bion casts 10 to 50 milligrams, and the bion of preferably daily per unit body weight (kg) casts 50 millis
Gram.
The mountain Soviet Union extract of the present invention has the active skull cap components for suppressing androgen, therefore, can be effectively improved by He Er
The caused disease of body imbalance, the particularly related disease of male prostate are suffered, and side effect will not be caused.The mountain Soviet Union extraction
Thing can be obtained by industrialization or by supercritical extraction step, and be applied to treat or prevent the medicine of prostatic diseases
Thing constitutes the exploitation of part or health food, is effect of the present invention to improve the problem of male prostate.
Description of the drawings
Fig. 1 is the chemical structural drawing of the Methyl Pyropheophorbide of the present invention.
Fig. 2 is the chemical structural drawing of the Enfoliative cytologic of the present invention.
Fig. 3 is the chemical structural drawing of the 1- linoleic acid -3- linolenic acid-glyceride of the present invention.
Fig. 4 is the chemical structural drawing of the 1- linolenic acid -2,3- Shuan Zong Beam-at-the-eaves acid-glyceride of the present invention.
Fig. 5 is the chemical structural drawing of the 1,3- bis- Zong Beam-at-the-eaves acid-glyceride of the present invention.
Fig. 6 is the extracting process flow chart of mountain Soviet Union of the present invention extract.
Fig. 7 is that mountain of the present invention Soviet Union extract purges with section figure.
Fig. 8 is the another extracting process flow chart of mountain Soviet Union of the present invention extract.
Fig. 9 is that extract is revived for the inhibition schematic diagram of androgen in mountain of the present invention.
Figure 10 is that extract is revived for the inhibition schematic diagram of androgen in mountain of the present invention.
Figure 11 is that extract is revived for the inhibitory action schematic diagram of prostate basic unit myofibroblast in mountain of the present invention.
Figure 12 is that extract is revived for the inhibitory action schematic diagram of Prostatic cancer cell lines in mountain of the present invention.
Figure 13 is the dosage and the graph of a relation for suppressing prostate gland cancer cell ability of mountain Soviet Union of the present invention extract.
Figure 14 a are that mountain of the present invention Soviet Union extract reduces mouse prostate index schematic diagram.
Figure 14 b are that mountain of the present invention Soviet Union extract lifts mice voided volume schematic diagram.
Figure 14 c are that mountain of the present invention Soviet Union extract reduces mice amount of drinking water schematic diagram.
Figure 15 is the pathological characters schematic diagram that mountain Soviet Union of the present invention extract suppresses prostate hyperplasia.
(present invention)
S1 solvent extractions
S2 col-umn chromatography steps
S3 selecting and purchasing steps.
Specific embodiment
Be allow the present invention above and other objects, features and advantages can become apparent, it is cited below particularly the present invention compared with
Good embodiment, and coordinate accompanying drawing, it is described in detail below：
Refer to shown in Fig. 1 to Fig. 5, the mountain Soviet Union extract of the present invention, comprising the pyropheophorbide-a first shown in the Fig. 1
Ester (pyropheophorbide a methyl ester；C34H36N4O-, account for mountain Soviet Union extract gross weight 5%), the Fig. 2
Shown Enfoliative cytologic (pheophorbide a methyl ester；C35H36N4O5, account for the mountain Soviet Union extract total
3.4%) the 1- linoleic acid -3- linolenic acid-glyceride (1-linleoyl-3-linolenoyl-, shown in the Fig. 3 of weight
glycerol；C39H66O5, account for 1- linolenic acid -2 2.9%), shown in the Fig. 4 of mountain Soviet Union extract gross weight, 3- bis- Zong Beam-at-the-eaves
Acid-glyceride (1-linleoyl-2,3-dipalmitoyl-rac-glycerol；C53H98O6, account for the mountain Soviet Union extract gross weight
5.4%), and 1, the 3- bis- Zong Beam-at-the-eaves acid-glyceride (1,3-dipalmitoyl-sn-glycerol shown in the Fig. 5；
C35H68O5, account for mountain Soviet Union extract gross weight 7.3%).The mountain Soviet Union extract can effectively suppress the secretion of androgen and anti-
Inflammation, so as to improve prostatic diseases.
Refer to shown in Fig. 6, mountain Soviet Union extract of the invention is that the extracting process by comprising the steps of is obtained：It is molten
Agent extraction step S1 and col-umn chromatography step S2.Solvent extraction S1, be use 95% ethanol or water as extraction
Solvent, to a mountain Soviet Union sample extraction processing is carried out, and obtains an extract, wherein the weighing body of mountain Soviet Union's sample and the extractant
Product is 50 to 60mg/mL than (w/v, g/ml).
Col-umn chromatography step S2, is that, with silica gel tubing string as fixing phase, water and ethanol carry out the extract as mobile phase
Chromatography process, to obtain several differentiators, it is section a to section i that the differentiator is successively numbered according to washing, picks constituency
Section b, c, d or its combination, Jing after concentrating under reduced pressure and freeze-drying process, obtain final product the mountain Soviet Union extract of the present invention.
In more detail, col-umn chromatography step S2 is carried out using automatization medium-sized tubing string liquid chromatograph (Flash LC)
The chromatography of the extract is processed, preferably from protein purification reaction phase post (reverse phase column) of C18
As fixing phase, to lift extraction yield, then sequentially purged with using the mobile phase of different proportion, Fractional Collections purges with liquid and obtains
Several differentiators, as shown in Figure 7.Priority that several differentiators are purged with according to it and respectively section a to i, capture section b,
C, d or combinations thereof obtain final product the mountain Soviet Union extract of the present invention Jing after concentrating under reduced pressure and lyophilization.Wherein, flowing of the invention
It is mutually that linear gradient is mixed into by ethanol and water, the mixing of the ethanol and water is to be promoted to 100% ethanol (V/ by 70% ethanol
V)。
Refer to shown in Fig. 8, the mountain Soviet Union extract of the present invention is more preferably before solvent extraction S1, first to operate one
It is the mountain Soviet Union sample that selecting and purchasing step S3, i.e. choosing pluck whole strain mountain Soviet Union flower containing root, and the mountain Soviet Union extract higher to obtain active component should
Mountain Soviet Union sample may be selected from Yushan Hill Soviet Union flower (Asplenium antiquum Makino；Also known as new pteris fern, Neottopteris nidus (L.) J. Smith) or Taiwan mountain Soviet Union flower
(Asplenium nidus Linn；Also known as Taiwan Neottopteris nidus (L.) J. Smith, Taiwan new pteris fern), preferably using Taiwan mountain Soviet Union flower (Asplenium
Nidus Linn) whole strain contain root, Taiwan mountain Soviet Union flower TaiWan, China distribution and planted area it is wider, can whole year production,
Preparation and raw material relatively beneficial to mountain of the present invention Soviet Union extract is obtained, furthermore, Taiwan mountain Soviet Union flower mostly is the cleaning vegetable without agricultural pollution
The problems such as dish, few pest and disease damage or pollution by pesticides, the safety of mountain Soviet Union of the present invention extract can be lifted.
The present invention mountain Soviet Union extract Jing scientific validation and confirm with anti-inflammatory and suppress androgen effective ingredient, bag
Containing Methyl Pyropheophorbide, Enfoliative cytologic, 1- linoleic acid -3- linolenic acid-glyceride, 1- linolenic acid -2,
3- bis- Zong Beam-at-the-eaves acid-glyceride and 1,3- bis- Zong Beam-at-the-eaves acid-glyceride, therefore, controllable plays expectation function in hormone receptor, enters
And improve by the caused disease of hormone receptor imbalance, such as prostatic diseases (include benign prostatauxe, prostate
Cancer and prostatitis), men and women's urinary incontinence, men and women's male bald and Women’s climacteric obstacle etc..
Also, the mountain Soviet Union extract can be easy to extract, separate, and there are the potentiality for being applied to new drug development.Will the mountain Soviet Union
Extract is applied to treat or prevent medicine group composition or the exploitation of health food of aforementioned diseases as an active component, special
It is not to improve the medicine group composition or health food of prostatic diseases, and then improves compatriots' health problem.The present invention
Mountain Soviet Union extract can be used alone in related drugs group composition or health food exploitation, or collocation pharmaceutically may be used
The supporting agent of acceptance, excipient, salt or other nutritional labelings etc. and combine a complex.Additionally, mountain Soviet Union extract more can be with
It is prepared into by being processed further any suitable for oral dosage form, such as lozenge, capsule, powder, pill, liquor or fermented product
Deng, or combine to make the food pattern for being more suitable for taking with other Foods or drinkses.
To confirm that the mountain Soviet Union extract of the present invention has the function of suppressing androgen, spy operation such as examination shown below really
Test, so its application is not limited thereto：
This test is, by aforesaid extracting process, sequentially to operate selecting and purchasing step S3, solvent extraction S1 and the pipe
Column chromatography steps S2, by the use of 95% ethanol the extraction processing of mountain Soviet Union sample is carried out as extractant, then medium-sized by the automatization
Tubing string liquid chromatograph, with the protein purification reaction phase post of C18 obtained nine section (a to i) are separated.Refer to figure
Shown in 9 and Figure 10, nine sections respectively with prostate gland cancer cell 22Rv/103E single culture, it is or thin with the carcinoma of prostate
Born of the same parents 22Rv/103E and prostate basic unit myofibroblast blast cell (stromal myofibroblast)-WPMY-1 co-cultivation,
Nine sections are determined respectively again for the inhibitory activity of androgen.
Its result shows, section b, c and d, with prostate gland cancer cell 22Rv/103E single culture (as shown in Figure 9), or
Person and prostate gland cancer cell 22Rv/103E103E and prostate basic unit myofibroblast blast cell (stromal
Myofibroblast) in the case of-WPMY-1 co-cultivation (as shown in Figure 10), there is significantly suppression to the androgen
Effect, and the dose proportional of the inhibition and the section b, c and d.
Refer to shown in Figure 11 and Figure 12, be nine sections to prostate basic unit myofibroblast blast cell-WPMY-1
And the impact of Prostatic cancer cell lines-LNCaP growths.Nine sections respectively with the prostate basic unit myofibroblast-
WPMY-1 and the Prostatic cancer cell lines-LNCaP cell co-cultures 48 hours, are entered using SRB stains to the cell after culture
Row dyeing, then its cytoactive is determined respectively.Its result shows that the section b, c and d can suppress the prostate basic unit into flesh really
The growth of fibroblast-WPMY-1 and the Prostatic cancer cell lines-LNCaP, and the inhibitory action and the section b, c and d
Dosage is into original.
Refer to shown in Figure 13, be the section b, c and d compositionss to the prostate basic unit myofibroblast blast cell-
WPMY-1 (1) and the impact of Prostatic cancer cell lines-LNCaP (2) growth.Using cell colony growth analytic process (colony
Formation assay) determine said composition at different dosages, to prostate basic unit myofibroblast blast cell-WPMY-1
And the rejection ability of the Prostatic cancer cell lines-LNCaP, its result shows, the dosage of said composition is with said composition to prostatitis
The rejection ability of adenocarcinoma cell growth is into positive relationship, also, the said composition of higher dosage (such as 100 μ g/mL) more can be made
Into prostate cancer cell death.Said composition is thin for the prostate basic unit myofibroblast-WPMY-1 and the carcinoma of prostate
Semi-inhibit dosage (the IC of born of the same parents strain-LNCaP50Value) it is respectively 11.63 μ g/mL and 13.19 μ g/mL.
Additionally, for confirm the present invention mountain Soviet Union extract can be effectively improved mouse prostate hypertrophy symptom, carry out then with
Lower test, precisely because application category is not limited thereto：
This test is to raise in Zhong Yan institutes from C57BL/6Jnar1 male mices (being purchased from National Animal Center), the mice
Agro-ecology Technological research center SPF Animal Houses, feeding environment is 22 DEG C, and light application time is respectively 12 hours with interlunation.
This test is that (phenylephrine, abbreviation PE, amount of application is per unit body with subcutaneous injection adrianol
Weight kilogram bestows 15 milligrams of adrianols), to activate α 1- adrenoceptors, and then inducing mouse produces prostate fertilizer
Big phenomenon (being to inject five adrianols, and continuously injection five weeks weekly during its induction)；And while oral feeding
The mountain Soviet Union of the invention extract of various dose, observe test mice prostate index (prostate index, abbreviation PI,
That is prostate inside line weight in wet base/Mouse Weight), mice urination situation and drinking-water situation, be embedded in respectively Figure 14 a, Figure 14 b and
Figure 14 c；And in sacrificing after mice, taking its prostate carries out section statining, and its result is as shown in figure 15.
Refer to shown in Figure 14 a, compared to control group, bestow the prostate index of the mice (PE groups) of adrianol
Significantly rise, represent that the mice produces the phenomenon of prostate inside line enlargement, the mice has urination to reduce simultaneously, and drinking-water
The phenomenons such as amount reduction；And while feeding mountain Soviet Union wine extracts thing, (ANE groups, without col-umn chromatography step, dosage is daily per unit body weight
Kilogram 100 milligrams of mouse feeding) or the present invention mountain Soviet Union extract (Lo groups, dosage be daily per unit body weight kilogram mice hello
10 milligrams of food；Or Hi groups, daily 50 milligrams of per unit body weight kilogram mouse feeding) can effectively slow down mouse prostate index
Change, it is also possible to alleviate mice urination reduce and amount of drinking water increase problem (p ＜ 0.01 refer to Figure 14 b and Figure 14 c),
Wherein, with the best results on the mountain of the present invention Soviet Union's extract (Hi groups) of daily 50 milligrams of per unit body weight kilogram mouse feeding.It is
So that the mountain Soviet Union extract of the present invention can effectively alleviate the prostate hyperplasia phenomenon of organism.
Then, after by above-mentioned five groups of mices (control group, PE groups, ANE groups, Lo groups and Hi groups) sacrifice, taking prostate is carried out
Section, and hematoxylin-eosin staining (Hematoxylin-eosin staining, abbreviation H＆E staining) is carried out, compare
In control group, the mice (PE groups) of adrianol is bestowed it is observed that epithelial hyperplasia phenomenon, secretes PE group mices
Urethra chamber area is substantially reduced, and represents that the secretion body of gland of PE group mices is subject to compress (as shown in the ii of Figure 15), and while feeding
Mountain Soviet Union's extract (Lo groups or Hi groups) of food mountain Soviet Union's wine extraction thing (ANE groups) or the present invention can effectively slow down above-mentioned epithelial cell
Hypertrophy phenomenon (as shown in iii, iv and v of Figure 15).
Additionally, refer to shown in the vii to xi of Figure 15, this test is more with prunus mume (sieb.) sieb.et zucc. Sheng Shi trichrome stainings (Masson ' s
Trichrome staining), observe the distribution situation of the collagen protein of each group section, the collagen protein distribution of control group
It is relatively wide (as shown in the vii of Figure 15, yellow arrows indication blue region is collagen protein), more can observe in Prostate gland stroma
To the distribution (such as orange arrow indication region) of reticular fiber, and the section of PE group mices is then more difficult observes this phenomenon (such as
Shown in the viii of Figure 15), and while mountain Soviet Union's extract (Hi groups) of the feeding present invention then can effectively reply above-mentioned phenomenon (as schemed
Shown in 15 ix).
The prostate hyperplasia phenomenon that adrianol is caused therefore the mountain Soviet Union extract of the present invention can effectively releive,
Increase mice voided volume, and the pathological characters that prostate hyperplasia is caused can also be slowed down, can be used as improving male prostate
The active substance of problem, is applied to prepare the medicine group composition or health food to treat prostatosis.
The practical application of mountain Soviet Union of the present invention extract is as shown in the embodiment of lower section, but its application is not limited with this example：
The present embodiment presses aforesaid extracting process, sequentially operates selecting and purchasing step S3, solvent extraction S1 and tubing string layer
Analysis step S2, so that the mountain Soviet Union extract is obtained.Refer to shown in the 1st table, the mountain Soviet Union extract is supplied to 88 all ages and classes layers
Patients of Prostatic Diseases take, the urination situation of patient can be improved in average two to four week, while not causing any secondary make
With contributing to the treatment of prostate hyperplasia, prostatitis or carcinoma of prostate.
One of symptom of prostate hyperplasia is exactly pollakiuria and nocturia, and the mountain Soviet Union extract of the present invention can be by pollakiuria and nocturia
Frequency is down to and is as good as with normal person.By the situation before and after aforementioned 88 patient tests, according to international contest table
(International Prostate Symptom Score, I-PSS) is analyzed, and progressive fraction is average extremely within 2 to 4 weeks
It is few to reach about 20 to 30 points, far above commercially available now with average 2-3 point of nutritional supplement product, and average 14 points of Drug therapy.
1st table:The use result that 88 prostatosis are suffered from
aPostoperative and anesthesia, urethra is stained with the postoperative proprietary symptom of glutinous not prostate hyperplasia or carcinoma of prostate.Severe patient is even
As long as procrastinateing several months sequela, general multiplex alpha-receptor blocker is relaxed.So, mountain of the invention Soviet Union extract has speed
Effect and the effects such as persistent, may be used to improve urethra and is stained with glutinous.
From the above, mountain of the invention Soviet Union extract has anti-inflammatory and suppresses the active skull cap components of androgen, therefore,
Can be effectively improved by the caused disease of hormone receptor imbalance, the particularly related disease of male prostate, and will not cause
Side effect.The mountain Soviet Union extract can be obtained by industrialization or by supercritical extraction step, and be applied to treat or prevented
The medicine group composition of prostatic diseases or the exploitation of health food, are the present invention's to improve the problem of male prostate
Effect.
Claims (4)
1. a kind of purposes of mountain Soviet Union extract, is that the mountain is revived extract as an active substance, is applied to prepare to control
Treat prostate hyperplasia, carcinoma of prostate and prostatitic medicine group composition；
Wherein, mountain Soviet Union's extract is sub- comprising Methyl Pyropheophorbide, Enfoliative cytologic, 1- linoleic acid -3-
Numb acid-glyceride, 1- linolenic acid -2,3- bis- Zong Beam-at-the-eaves acid-glyceride, and 1,3- bis- Zong Beam-at-the-eaves acid-glyceride, and include down by one
Mountain Soviet Union extract obtained by the method for row step：
One solvent extraction, i.e., extracted as an extractant using 95% ethanol or water to a mountain Soviet Union sample
Process is taken, makes mountain Soviet Union's sample and the amount volume ratio (w/v) of the extractant be 50～60mg/ml, and reclaim to obtain an extraction
Thing；And
One col-umn chromatography step, linear gradient is mixed into as mobile phase by the use of second alcohol and water, and with C18 protein purifications phase post is reacted
Used as fixing phase, the chromatography for carrying out the extract is processed, and the mixing of wherein ethanol and water is promoted to by 70% ethanol
100% ethanol (V/V), to obtain several differentiators, as shown in fig. 7, it is section a to i to number according to order is purged with, Xie Xuangai areas
The compositionss of section b, c, d or section b～d, Jing after concentrating under reduced pressure and lyophilization, obtain final product the mountain Soviet Union extract.
2. mountain as claimed in claim 1 is revived the purposes of extract, it is characterised in that mountain Soviet Union extract is with oral way throwing
Give a bion.
3. mountain as claimed in claim 1 is revived the purposes of extract, it is characterised in that the amount of casting of mountain Soviet Union extract is daily
The bion of per unit body weight (kg) casts 10 to 50 milligrams.
4. mountain as claimed in claim 3 is revived the purposes of extract, it is characterised in that the amount of casting of mountain Soviet Union extract is daily
The bion of per unit body weight (kg) casts 50 milligrams.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13887600.8A EP3015105A4 (en) | 2013-06-27 | 2013-12-25 | Asplenium nidus extract and use thereof |
| PCT/CN2013/090456 WO2014206048A1 (en) | 2013-06-27 | 2013-12-25 | Asplenium nidus extract and use thereof |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW101123087 | 2012-06-27 | ||
| TW101123087 | 2012-06-27 | ||
| TW102122748A TWI492754B (en) | 2012-06-27 | 2013-06-26 | Use of asplenium nidus linn. |
| TW102122748 | 2013-06-26 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410689932.1A Division CN104523766A (en) | 2012-06-27 | 2013-06-27 | Extract of Stachys sieboldii |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103505457A CN103505457A (en) | 2014-01-15 |
| CN103505457B true CN103505457B (en) | 2017-04-26 |
Family
ID=49889231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310261724.7A Active CN103505457B (en) | 2012-06-27 | 2013-06-27 | Application of stachys sieboldii extract |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103505457B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI615146B (en) * | 2017-07-14 | 2018-02-21 | 景鑫生物科技股份有限公司 | A use of an extract of asplenium australasicum (j. sm.) hook. |
| TWI624264B (en) * | 2017-08-11 | 2018-05-21 | 景鑫生物科技股份有限公司 | A use of an extract of asplenium australasicum (j. sm.) hook. |
| CN107836710B (en) * | 2017-11-22 | 2021-04-16 | 广东省农业科学院蚕业与农产品加工研究所 | High-absorptivity iron-supplementing peptide-rich food base material and preparation method and application thereof |
| CN110237107A (en) * | 2019-05-31 | 2019-09-17 | 嘉兴市爵拓科技有限公司 | Preparation method, its composition and its application of a kind of mountain Soviet Union extract |
-
2013
- 2013-06-27 CN CN201310261724.7A patent/CN103505457B/en active Active
Non-Patent Citations (1)
| Title |
|---|
| 鸟巢蕨水提取液对兔成骨细胞的影响;陈庆玉 等;《上海中医药杂志》;20111231;第45卷(第8期);第59－72页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103505457A (en) | 2014-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101411761B (en) | Novel use of plants in sorbus malus group of malus | |
| CN101199683B (en) | Chinese medicine for treating skin disease and preparing method thereof | |
| CN103505457B (en) | Application of stachys sieboldii extract | |
| CN104523766A (en) | Extract of Stachys sieboldii | |
| CN101229223B (en) | Applications of fructus psoraleae extractive on preparing antitumor medicines | |
| CN108434399A (en) | A kind of Chinese medicine composition and preparation method of anti-curing oncoma | |
| CN1907308A (en) | Chinese traditional medicine composition for treating tumour | |
| CN107812115A (en) | A kind of Chinese medicine composition for treating diabetes | |
| CN106421447A (en) | Medicine composition for controlling blood pressure and protecting blood vessels and preparation method and purpose thereof | |
| CN100446802C (en) | Crude drug for preventing tumor metastasis | |
| CN108452240B (en) | Anti-tumor traditional Chinese medicine composition and application thereof | |
| CN116251132B (en) | Nine-steaming nine-preparation bighead atractylodes rhizome extract and application | |
| CN104840747B (en) | Chinese medicine composition with antithyroid cancer activity and its preparation method and application | |
| CN102188459A (en) | Brucea javanica total terpenoid extractive, and preparation method and application thereof | |
| CN108186990A (en) | It is a kind of to be used to treat big drug of children's mesenteric adenophyma and preparation method thereof | |
| CN113101308B (en) | Angelica gigas nakai extract and preparation method and application thereof | |
| CN107875356A (en) | A kind of Chinese medicine preparation for treating gallbladder polyps and preparation method thereof | |
| CN107670016A (en) | It is a kind of for mastosis through percutaneous drug delivery product and preparation method thereof | |
| KR100528398B1 (en) | Extracts from Daphne genkwa having inhibitory effects on adipocytes (NIH3T3-L1 cell) | |
| CN1186062C (en) | Antiinflammatory hemostatic gynecologic medicine and use thereof | |
| CN101352562A (en) | Chinese medicine preparation for treating cardiovascular and cerebrovascular diseases and method for preparing the same | |
| CN105796615A (en) | Moringa oleifera effective ingredient capable of relieving intestinal injury and preparation method and application thereof | |
| CN110101780A (en) | A kind of pharmaceutical composition and preparation method thereof for treating lung cancer | |
| JP5909272B2 (en) | Method for producing an extract of Shimatani Watari | |
| JP5865318B2 (en) | Use of Shimatani Watari Extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1189350 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1189350 Country of ref document: HK |